ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > TLR3

TLR3

概要

Name:Toll like receptor 3
Target Synonym:CD283,TLR3,Toll Like Receptor 3,Toll-Like Receptor 3,CD283 Antigen,IIAE2
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
TL3-R5253 Rhesus macaque Rhesus macaque TLR3 / CD283 Protein, Fc Tag (MALS verified)
TL3-R5253-structure
TL3-R5253-sds
TL3-M5255 Mouse Mouse TLR3 / CD283 Protein, Fc Tag (MALS verified)
TL3-M5255-structure
TL3-M5255-sds
TL3-H5253 Human Human TLR3 Protein, Fc Tag (MALS verified)
TL3-H5253-structure
TL3-H5253-sds
ACRO Quality

生物活性データの一部

TL3-R5253-MALS-HPLC
TLR3 MALS images

The purity of Rhesus macaque TLR3 Protein, Fc Tag (Cat. No. TL3-R5253) is more than 90% and the molecular weight of this protein is around 260-290 kDa verified by SEC-MALS.

TL3-M5255-MALS-HPLC
Human TLR3, Fc Tag (Cat. No. ) MALS images

The purity of Human TLR3, Fc Tag (Cat. No. TL3-M5255) is more than 90% and the molecular weight of this protein is around 235-287 kDa verified by SEC-MALS.

Synonym Name

TLR3,CD283,IIAE2

Background

Toll-like receptor 3 (TLR3) is also known as CD283, which belongs to the Toll-like receptor family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 / CD283 contains 22 LRR (leucine-rich) repeats, 1 LRRCT domain, 1 LRRNT domain and 1 TIR domain. TLR3 is expressed at high level in placenta and pancreas and also detected in CD11c+ immature dendritic cells. CD283 / TLR3 is only expressed in dendritic cells. TLR3 is the TLR that is expressed most strongly in the brain, especially in astrocytes, glia, and neurons. CD283 / TLR-3 is the key component of innate and adaptive immunity. TLR3 / CD283 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. TLR3 acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Defects in TL-R3 are associated with herpes simplex encephalitis type 2 (HSE2).

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Rintatolimod AMP-516; AMP-518 Approved Hemispherx Biopharma Inc Rintamod, Ampligen Argentina Fatigue Syndrome, Chronic Hemispherx Biopharma Inc 2017-01-01 HIV Infections; Ovarian Neoplasms; Pancreatic Neoplasms; Mesothelioma; Influenza, Human; Breast Neoplasms; Post-Acute COVID-19 Syndrome; Peritoneal Neoplasms; Colorectal Neoplasms; Fatigue Syndrome, Chronic; Fallopian Tube Neoplasms; HIV Seropositivity; Breast Neoplasms, Male Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Monovalent norovirus Vaccine (Vaxart) VXA-G1-1-NN; VXA-G1.1-NN Phase 2 Clinical Vaxart Inc Norovirus Infections Details
TR-987 Z-101; GLYC-101; MG-3601 Phase 2 Clinical Kazia Therapeutics Wounds and Injuries; Varicose Ulcer Details
Poly ICLC (Oncovir) Phase 2 Clinical National Institutes Of Health, Oncovir Inc Prostatic Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, T-Cell; Glioma; Carcinoma, Squamous Cell; Colorectal Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Lymphoma, B-Cell; Sarcoma; Osteosarcoma; Mesothelioma; Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Glioblastoma; Carcinoma, Merkel Cell Details
BO-112 BO-112 Phase 2 Clinical Highlight Therapeutics SL Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular Details
Monovalent norovirus Vaccine (Vaxart)/VXA-G2-4-NS VXA-NVV-201 Phase 2 Clinical Vaxart Inc Norovirus Infections Details
CNTO-5 CNTO-5 Phase 1 Clinical Morphosys Ag Inflammation Details
PGV-001 PGV-001 Phase 1 Clinical Genentech Inc, Icahn School Of Medicine At Mount Sinai Neoplasms; Urologic Neoplasms Details

This web search service is supported by Google Inc.

totopphone